---
figid: PMC9489683__nihms-1826127-f0003
figtitle: Treg suppression of conventional T cells
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC9489683
filename: nihms-1826127-f0003.jpg
figlink: /pmc/articles/PMC9489683/figure/F3/
number: F3
caption: 'eTreg directly suppress Tconv cells through secretion of soluble mediators
  including immunosuppressive cytokines IL-10, IL-35, and TGF-β, through TIGIT-induced
  secretion of Fgl2, via enzymatic catabolism of soluble ATP and PGE2, and through
  scavenging of IL-2 in the milieu. Furthermore, eTregs induce a tolerogenic profile
  in APCs, triggering indirect suppression of Tconv activation, proliferation, and
  transcription of their pro-inflammatory factors. Indeed, eTregs induce expression
  of IDO in APCs, which activates the kynurenine pathway via CTLA-4 binding and results
  in tryptophan deprivation, reduced antigen presentation upon LAG-3 ligation, and
  decreased Tconv co-stimulatory signaling via CTLA-4. eTregs can also trigger death
  of the targeted cell upon binding to the death receptors FAS and TRAIL and by secretion
  of perforin and granzyme. Reinforcement of the eTreg phenotype occurs via PD-1/PD-L1
  engagement, semaphorin 4 binding to Nrp1, and IL-2-mediated signaling.A2A: adenosine
  A2A receptor; AhR: aryl hydrocarbon receptor; APC: antigen-presenting cell; cAMP:
  cyclic adenosine monophosphate; CREB: C-responsive element binding; CTLA-4: cytotoxic
  T-lymphocyte-associated protein 4; eATP: extracellular adenosine triphosphate; eTreg
  : effector regulatory T cell; Fgl2: fibrinogen-like protein 2; GCN2: general control
  nonderepressible 2; HPGD: 15-hydroxyprostaglandin dehydrogenase; IDO: indoleamine
  2,3-dioxygenase; LAG-3: lymphocyte-activation gene-3; MHC II: major histocompatibility
  complex II; mToRC: mammalian target of rapamycin; NFAT: nuclear factor of activated
  T cells; NF-κb: nuclear factor kappa-light-chain-enhancer of activated B cells;
  Nrp1: Neuropillin 1; PPARγ: peroxisome proliferator-activated receptor-γ; PD-1:
  programmed cell death protein 1; PD-L1: programmed death-ligand 1; PGE2: prostaglandin
  E2; STAT: signal transducer and activator of transcription; Tconv: conventional
  T cell; TCR: T cell-receptor; TGF-β: transforming growth factor beta; TIGIT: T cell
  immunoreceptor with Ig and ITIM domain; TRAIL: TNF-related apoptosis-inducing ligand.'
papertitle: 'Neuroinflammation: extinguishing a blaze of T cells.'
reftext: Nail Benallegue, et al. Immunol Rev. ;311(1):151-176.
year: '2023'
doi: 10.1111/imr.13122
journal_title: Immunological reviews
journal_nlm_ta: Immunol Rev
publisher_name: ''
keywords: T cells | Th cells | Tregs | central nervous system | inflammation | autoimmunity
automl_pathway: 0.9598725
figid_alias: PMC9489683__F3
figtype: Figure
redirect_from: /figures/PMC9489683__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9489683__nihms-1826127-f0003.html
  '@type': Dataset
  description: 'eTreg directly suppress Tconv cells through secretion of soluble mediators
    including immunosuppressive cytokines IL-10, IL-35, and TGF-β, through TIGIT-induced
    secretion of Fgl2, via enzymatic catabolism of soluble ATP and PGE2, and through
    scavenging of IL-2 in the milieu. Furthermore, eTregs induce a tolerogenic profile
    in APCs, triggering indirect suppression of Tconv activation, proliferation, and
    transcription of their pro-inflammatory factors. Indeed, eTregs induce expression
    of IDO in APCs, which activates the kynurenine pathway via CTLA-4 binding and
    results in tryptophan deprivation, reduced antigen presentation upon LAG-3 ligation,
    and decreased Tconv co-stimulatory signaling via CTLA-4. eTregs can also trigger
    death of the targeted cell upon binding to the death receptors FAS and TRAIL and
    by secretion of perforin and granzyme. Reinforcement of the eTreg phenotype occurs
    via PD-1/PD-L1 engagement, semaphorin 4 binding to Nrp1, and IL-2-mediated signaling.A2A:
    adenosine A2A receptor; AhR: aryl hydrocarbon receptor; APC: antigen-presenting
    cell; cAMP: cyclic adenosine monophosphate; CREB: C-responsive element binding;
    CTLA-4: cytotoxic T-lymphocyte-associated protein 4; eATP: extracellular adenosine
    triphosphate; eTreg : effector regulatory T cell; Fgl2: fibrinogen-like protein
    2; GCN2: general control nonderepressible 2; HPGD: 15-hydroxyprostaglandin dehydrogenase;
    IDO: indoleamine 2,3-dioxygenase; LAG-3: lymphocyte-activation gene-3; MHC II:
    major histocompatibility complex II; mToRC: mammalian target of rapamycin; NFAT:
    nuclear factor of activated T cells; NF-κb: nuclear factor kappa-light-chain-enhancer
    of activated B cells; Nrp1: Neuropillin 1; PPARγ: peroxisome proliferator-activated
    receptor-γ; PD-1: programmed cell death protein 1; PD-L1: programmed death-ligand
    1; PGE2: prostaglandin E2; STAT: signal transducer and activator of transcription;
    Tconv: conventional T cell; TCR: T cell-receptor; TGF-β: transforming growth factor
    beta; TIGIT: T cell immunoreceptor with Ig and ITIM domain; TRAIL: TNF-related
    apoptosis-inducing ligand.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PVR
  - APC
  - PROC
  - IL10
  - NRP1
  - NELL1
  - FGL2
  - IDO1
  - TGFB1
  - TGFB2
  - TGFB3
  - TIGIT
  - LAG3
  - CD274
  - IL2RA
  - ISG20
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CTLA4
  - CD80
  - CD86
  - HLA-C
  - IL2
  - ENTPD1
  - NT5E
  - HPGD
  - FASLG
  - TNFRSF10B
  - CD28
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - FAS
  - FASN
  - TNFSF10
  - NFATC1
  - NFATC2
  - NFATC3
  - NFATC4
  - NFAT5
  - NFKB1
  - EIF2AK4
  - AHR
  - STAT3
  - IGKV2D-29
  - CREB1
  - CREB3
  - CREB5
  - CREB3L1
  - CREB3L2
  - CREB3L3
  - CREB3L4
  - CREM
  - ATF1
  - ATF2
  - IL10RA
---
